Liquidity (Details) $ in Thousands		1 Months Ended		3 Months Ended		6 Months Ended		12 Months Ended
	Dec. 15, 2025 employee	Jan. 31, 2026 USD ($)	Dec. 31, 2025 USD ($)	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)	Jun. 30, 2025 USD ($)	Feb. 12, 2026 USD ($)
Liquidity
Net loss				$ 22,774	$ 15,730	$ 40,924	$ 31,108	$ 74,400
Net cash used in operating activities						37,754	$ 29,680	69,100
Accumulated deficit			$ 444,780	444,780		444,780		403,856
Cash and cash equivalents			11,944	11,944		11,944		94,107
Short-term investments			120,994	120,994		120,994		73,751
Total liabilities			10,631	10,631		10,631		13,363
Current liabilities			9,529	9,529		9,529		$ 11,912
Reduction in workforce | employee	29
One-time severance expenses			1,500	1,500		1,500
One-time severance benefits			$ 1,500	$ 1,500		1,500
Subsequent Events
Liquidity
One-time severance benefits		$ 0							$ 0
Payments related to one-time severance benefits		$ 1,500
XOMA (US) LLC | US Clinical Trial Rz358 (ersodetug) | Xoma License Agreement | Upon Regulatory Approval
Liquidity
Milestone closing payment						$ 25,000